SANTA MONICA, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Pharma
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
For Media: Justin Jackson
For Investor Inquiries: Lisa Burns and Nancy Yu
Source: Kite Pharma, Inc.
News Provided by Acquire Media